ArticleAJOG global reports2026
Predictive factors for long-term survivors in advanced-stage epithelial ovarian cancer.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost women with epithelial ovarian cancer present with advanced-stage disease and have poor survival outcomes. However, the factor associated with long-term survival and the prognostic impact of histologic subtype in this population remain incompletely characterized.
objectiveTo identify factors associated with long-term survival and to compare survival outcomes across histologic subtypes in advanced-stage epithelial ovarian cancer. STUDY
designWe conducted a retrospective cohort study of 359 women with stage III to IV epithelial ovarian cancer. Multivariable logistic regression analysis was used to identify independent predictors of long-term survival, defined as overall survival of 5 years or longer. Cox proportional hazards models were applied to evaluate survival outcomes.
resultsAmong patients with advanced-stage epithelial ovarian cancer, 109 patients (30.4%) achieved long-term survival. Median follow-up was 111.8 months.
conclusionLong-term survival in advanced-stage epithelial ovarian cancer is independently associated with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.